By Shayla Love — 2022
Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.
Read on www.vice.com
CLEAR ALL
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
1
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).
Society has started to become more accepting of our work and MAPS’ goal of mainstreaming psychedelic medicine seems closer than ever to being achieved,” explains MAPS Policy and Advocacy Director Natalie Ginsberg, M.S.W., in an interview with Jessica Semaan of Seismic Sisters.
In an appropriate context, ayahuasca can be a valuable therapeutic tool and can act as a catalyst that can render psychotherapeutic processes more effective in less time, and sometimes allow for critical interventions when several other therapeutic strategies have been unsuccessful.
Badass women making waves in the psychedelic movement, from research to drug policy reform.
Though researchers are still trying to understand the cognitive and therapeutic mechanics of psychedelics, they have concluded that psilocybin, DMT and other psychoactive chemicals can help people feel more tolerance, understanding and empathy.
While we can now begin to glimpse an end to the drug war, it is much harder to envision what the drug peace will look like. How will we fold these powerful substances into our society and our lives so as to minimize their risks and use them most constructively?
The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry